ASCO18: 3 unanswered questions from oncology's largest conference

Each year, the ASCO annual meeting serves as a forum for some of the most important clinical studies in oncology, giving physicians important insights into how best to treat patients with cancer. But the results are not always clear cut, particularly in the rapidly advancing field of immunotherapy. Below are three pressing questions researchers are still grappling to answer: